Ladenburg raised the firm’s price target on Core Scientific to $15 from $14.50 and keeps a Buy rating on the shares. After emerging from bankruptcy in late January, Core Scientific reported “surprisingly strong” Q2 results, says the analyst, who is revising the firm’s earnings models for 2024 and 2025 to account for the results from Q2 and management’s comments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORZ: